[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 3029 Reported in House (RH)] Union Calendar No. 654 119th CONGRESS 2d Session H. R. 3029 [Report No. 119-751] To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 28, 2025 Ms. Salinas (for herself and Mr. McCormick) introduced the following bill; which was referred to the Committee on Science, Space, and Technology July 16, 2026 Additional sponsors: Ms. McBride and Mr. Riley of New York July 16, 2026 Committed to the Committee of the Whole House on the State of the Union and ordered to be printed _______________________________________________________________________ A BILL To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
HR 3029 - 119
Reported in House
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
4
Sections
1
Dollar amounts
1
Deadlines and effective dates
Jul 16, 2026
Text version date
Largest fiscal amounts
$5,000,000 1
Top statutory references
42 U.S.C. 18931 1
Public Law 117-167 1
Deadline phrases
Not later than 1
Official source
Official PDF
Preview the source PDF from the official text formats without leaving this page, or open the original file in a new tab.
Structured text
Sec. 1.
SECTION 1. SHORT TITLE.
SECTION 1. SHORT TITLE. This Act may be cited ``Nucleic Acid Standards for Biosecurity Act''.
Sec. 2.
SEC. 2. SUPPORTING NUCLEIC ACID SCREENING.
SEC. 2. SUPPORTING NUCLEIC ACID SCREENING.
Sec. 10221
Section 10221 of the Research and Development, Competition, and
Section 10221 of the Research and Development, Competition, and Innovation Act (42 U.S.C. 18931; enacted as part of title II of division B of Public Law 117-167) is amended-- (1) in subsection (a)(1)-- (A) in subparagraph (C), by striking ``and'' after the semicolon; (B) by redesignating subparagraph (D) as subparagraph (E); and (C) by inserting after subparagraph (C) the following new subparagraph: ``(D) best practices, guidelines, and technical standards for risk management associated with engineering biology and biomanufacturing, including risks associated with the use of artificial intelligence; and''; (2) by redesignating subsections (b) and (c) as subsections (c) and (d), respectively; and (3) by inserting after subsection (a) the following new subsection: ``(b) Nucleic Acid Synthesis Screening Tools and Standards.-- ``(1) In general.--The Director, in consultation with heads of Federal agencies the Director considers appropriate, shall carry out measurement research to support the development and improvement of best practices and technical standards for biosecurity measures related to nucleic acid synthesis, including the following: ``(A) Testing to improve the accuracy, efficacy, and reliability of screening for nucleic acid synthesis. ``(B) Best practices, including security and access controls, for operational security and managing sequence-of-concern databases to support such screening. ``(C) Technical implementation guidance to ensure such screening is effective and secure. ``(D) Conformity-assessment best practices and technical standards. ``(E) Methods to evaluate the impact and effectiveness of the implementation of subparagraphs (A) through (D). ``(2) Consortium.--In carrying out this subsection, the Director shall convene a consortium of stakeholders, including industry, institutions of higher education, nonprofit organizations, and customers to carry out the following: ``(A) Develop and periodically update consensus priorities and best practices, as appropriate, for synthetic nucleic acid procurement screening mechanisms. ``(B) Develop roadmaps to inform the activities carried out under paragraph (1). ``(3) Report.--Not later than 18 months after the first meeting of the consortium under paragraph (2), the Director shall submit to the Committee on Commerce, Science, and Transportation of the Senate and the Committee on Science, Space, and Technology of the House of Representatives a report summarizing the findings of the consortium. ``(4) Authorization of appropriations.--Of the funds authorized to be appropriated for the National Institute of Standards and Technology pursuant to this section for scientific and technical research and services laboratory activities, there is authorized to be appropriated $5,000,000 for each of fiscal years 2026 through 2030 to carry out this subsection.''. Union Calendar No. 654 119th CONGRESS 2d Session H. R. 3029 [Report No. 119-751] _______________________________________________________________________ A BILL To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes. _______________________________________________________________________ July 16, 2026 Committed to the Committee of the Whole House on the State of the Union and ordered to be printed
Cached official text analysis. This viewer uses cached official bill text and deterministic section, phrase, fiscal, agency, deadline, and statutory-reference extraction. The analysis is navigation support, not a legal interpretation; consult the official text for authoritative wording.
Sign in to use bill text research tools
Text find, signal filters, structured drilldowns, match navigation, and bill text bookmarks are account features. Create a free account to use them and return to this bill text.